Core Viewpoint - Akari Therapeutics has appointed Dr. Olga Anczukow to its Scientific Advisory Board, enhancing its expertise in RNA biology and cancer research, which is crucial for the development of next-generation therapeutics [1][2][4] Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing antibody drug conjugates (ADCs) with a unique payload, PH1, that targets RNA splicing in cancer cells [9] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [9] - AKTX-101 has shown significant activity in preclinical studies, demonstrating prolonged survival compared to traditional ADCs and potential synergy with checkpoint inhibitors [9] Dr. Olga Anczukow's Background - Dr. Anczukow is a recognized leader in RNA biology and cancer research, currently serving as an Associate Professor at The Jackson Laboratory for Genomic Medicine and a Co-Program Leader at the NCI-designated Jackson Laboratory Cancer Center [4][6] - Her research focuses on alternative RNA splicing and its misregulation in cancer, contributing to tumor initiation, progression, and therapeutic resistance [4][6] - Dr. Anczukow's previous work includes significant contributions to understanding breast cancer genetics and the role of RNA splicing in cancer biology [5][6] Research and Development Focus - The company aims to leverage Dr. Anczukow's expertise to shape research strategy and evaluate emerging scientific opportunities, particularly in RNA-targeted treatments [2][4] - Akari's innovative ADC discovery platform allows for the generation and optimization of ADC candidates tailored to specific antigen targets [9] - The ongoing research at The Jackson Laboratory integrates various methodologies to investigate how cancer cells adapt their splicing programs to survive and evade therapy [6]

LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into an amendment to its royalty purchase agreement with entities managed by HealthCare Royalty. ® Based on confidence in the long-term outlook for ZYNLONTA, ADC Therapeutics negotiated mutually beneficial updated terms with HealthCare Royalty, offering greater strategic flexibility to the Comp ...

Advancing Antibody Drug Conjugates With Novel Immuno-Oncology Payloads Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc (the "Company") that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or re ...

Unmasking Advances in Oncology 44th Annual JP Morgan Healthcare Conference Dr. Sean McCarthy, CEO and Chairman January 14, 2026 © 2026 CytomX Therapeutics, Inc. 1 Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events, including those related to varsetatug masetecan and CX-801. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, techno ...

Strategic Overview and Pipeline - Innate Pharma is focusing on strong R&D execution in 2024/2025 with key assets like IPH6501, IPH4502, and Lacutamab[12] - The company has a robust pipeline of innovative assets, including NK-cell engagers, antibody-drug conjugates (ADCs), and monoclonal antibodies, across various stages of development[20] - Lacutamab has positive Phase 2 data and received FDA Breakthrough Therapy Designation, with partnership discussions underway[13, 19] - IPH4502 (Nectin-4) IND was cleared, and Phase 1 First Patient In (FPI) is expected in January 2025[13, 17] ANKET® & ADC Programs - Innate Pharma is developing multiple ANKET® programs targeting hematological malignancies and solid tumors, including SAR'579/IPH6101 (CD123), SAR'514/IPH6401 (BCMA), and IPH6501 (CD20-IL2v)[26, 27] - IPH4502 is a novel Nectin-4 ADC with a DAR of 8, designed for improved therapeutic index and efficacy in Nectin-4 expressing solid tumors[30, 33] Financial Highlights - The company reported revenue/other income from continuing operations of €20.1 million in 2024, including €12.6 million from licensing and collaborations and €7.5 million from government funding for research expenditures[58] - Operating expenses from continuing operations were €71.7 million, with 73% related to R&D[58] - Cash, cash equivalents, and financial assets totaled €91.1 million as of December 31, 2024, providing a runway to mid-2026[59] Upcoming Catalysts - Upcoming catalysts include Phase 1 safety and preliminary efficacy data for IPH6501 and IPH4502, as well as partnering discussions and Phase 3 plans for Lacutamab[62]